Precision Wealth Strategies LLC Buys New Position in Medpace Holdings, Inc. $MEDP

Precision Wealth Strategies LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 1,524 shares of the company’s stock, valued at approximately $784,000.

Other large investors also recently modified their holdings of the company. CWM LLC grew its stake in shares of Medpace by 311.4% in the third quarter. CWM LLC now owns 28,496 shares of the company’s stock worth $14,652,000 after acquiring an additional 21,569 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of Medpace by 159.4% during the third quarter. Pacer Advisors Inc. now owns 111,290 shares of the company’s stock valued at $57,221,000 after buying an additional 68,384 shares during the last quarter. Norden Group LLC lifted its stake in shares of Medpace by 10.0% in the third quarter. Norden Group LLC now owns 1,234 shares of the company’s stock valued at $634,000 after buying an additional 112 shares during the period. Parcion Private Wealth LLC acquired a new stake in Medpace during the third quarter worth about $392,000. Finally, HBK Sorce Advisory LLC increased its stake in Medpace by 7.7% during the third quarter. HBK Sorce Advisory LLC now owns 6,010 shares of the company’s stock valued at $3,191,000 after acquiring an additional 429 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Medpace

In related news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kevin M. Brady sold 3,000 shares of the stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the sale, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $3,542,100. This represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 387,925 shares of company stock worth $233,386,647. Insiders own 20.30% of the company’s stock.

Medpace Trading Up 0.4%

NASDAQ MEDP opened at $572.00 on Friday. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26. The company has a 50 day moving average of $578.83 and a 200-day moving average of $478.30. The firm has a market cap of $16.11 billion, a price-to-earnings ratio of 40.00, a PEG ratio of 2.16 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same period in the prior year, the company earned $3.01 EPS. Medpace’s revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of research reports. Rothschild Redb cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Rothschild & Co Redburn lowered shares of Medpace from a “buy” rating to a “neutral” rating and boosted their price target for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Barclays raised their price objective on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Finally, Robert W. Baird set a $613.00 price target on shares of Medpace in a research note on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $490.82.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.